Chapter 1. Introduction1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive SummaryChapter 4. Market Outlook4.1. Market Dynamics
4.1.1. Market Drivers
4.1.2. Market Restraints
4.1.3. Market Opportunities
4.2. Porter’s Analysis
4.3. Value Chain Analysis
Chapter 5. Liver Cirrhosis Treatment Market, By Disease Type5.1. Liver Cirrhosis Treatment Market, by Disease Type, 2018-2026
5.2. Hepatitis C-Related Cirrhosis
5.3 Alcoholic Cirrhosis
5.4 Primary Sclerosing Cholangitis
5.5 Primary Biliary Cirrhosis
Chapter 6. Liver Cirrhosis Treatment Market, By Drug Type6.1. Liver Cirrhosis Treatment Market, by Drug Type, 2018-2026
6.2.Chemotherapeutic Drugs
6.3 Targeted Therapy
6.4 Vaccines
6.5 Antiviral Drugs
6.6 Immunoglobulins
6.7 Corticosteroids
6.8 Immunosuppressants
Chapter 7. Liver Cirrhosis Treatment Market, By Regions7.1. Liver Cirrhosis Treatment Market, by Region, 2018-2026
7.1.1. North America
7.1.1.1. U.S
7.1.1.2. Rest of North America
7.1.2. Europe
7.1.2.1. U.K.
7.1.2.2. Germany
7.1.2.3. France
7.1.2.4. Rest of the Europe
7.1.3. Middle East & Africa (MEA)
7.1.3.1. GCC
7.1.3.2. North Africa
7.1.3.3. South Africa
7.1.3.4. Rest of MEA
7.1.4. Latin America (LATAM)
7.1.4.1. Brazil
7.1.4.2. Rest of LATAM
7.1.5. Asia Pacific (APAC)
7.1.5.1. India
7.1.5.2. China
7.1.5.3. Japan
7.1.5.4. Rest of the APAC
Chapter 8. Competitive Landscape8.1.1. Key Strategies Adopted by Players
8.1.2. Market Share/Positioning Analysis
Chapter 9. Company Profiles
9.1. Pfizer, Inc.9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Abbott Laboratories9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Merck & Co., Inc.9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Novartis AG9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. F. Hoffmann-La Roche Ltd9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Takeda Pharmaceuticals Company Ltd9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Zydus Pharmaceuticals Inc9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. Gilead Sciences9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. GlaxoSmithKline9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
9.10. Intercept Pharmaceuticals9.10.1. Company Overview
9.10.2. Product Offerings
9.10.3. Financial Performance
9.10.4. Recent Initiatives
9.11 Conatus Pharmaceuticals
9.11.1. Company Overview
9.11.2. Product Offerings
9.11.3. Financial Performance
9.11.4. Recent Initiatives
9.12 Janssen Pharmaceuticals
9.12.1. Company Overview
9.12.2. Product Offerings
9.12.3. Financial Performance
9.12.4. Recent Initiatives
9.13 Instituto Grifols
9.13.1. Company Overview
9.13.2. Product Offerings
9.13.3. Financial Performance
9.13.4. Recent Initiatives
9.14 Gwo Xi Stem Cell Applied Technology
9.14.1. Company Overview
9.14.2. Product Offerings
9.14.3. Financial Performance
9.14.4. Recent Initiatives
Chapter 10. Appendix10.1. About Us
10.2. Glossary of Terms